Rokeya Tasneen

2.5k citations

35 papers · 1.7k indexed · h-index 20

Co-authors: Eric L. Nuermberger Kathy N. Williams Sandeep Tyagi J Grosset Khisimuzi Mdluli Deepak V. Almeida Charles A. Peloquin Si-Yang Li
Topics: Tuberculosis Research and Epidemiology (30 papers)Mycobacterium research and diagnosis (15 papers)Cancer therapeutics and mechanisms (11 papers)
Cited by: Infectious Diseases Molecular Medicine Epidemiology
Journals: Nature Communications American Journal of Respiratory and Critical Care Medicine The Journal of Infectious Diseases
Partner nations: United States China France

In The Last Decade

Rokeya Tasneen

35 papers receiving 1.6k citations

Peers

Countries citing papers authored by Rokeya Tasneen

Since Specialization

Citations

This map shows the geographic impact of Rokeya Tasneen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rokeya Tasneen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rokeya Tasneen more than expected).

Fields of papers citing papers by Rokeya Tasneen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rokeya Tasneen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rokeya Tasneen. The network helps show where Rokeya Tasneen may publish in the future.

Co-authorship network of co-authors of Rokeya Tasneen

This figure shows the co-authorship network connecting the top 25 collaborators of Rokeya Tasneen. A scholar is included among the top collaborators of Rokeya Tasneen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rokeya Tasneen. Rokeya Tasneen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen 2024 ·Nature Communications ·Natasha Strydom,(unknown),Marjorie Z. Imperial,(unknown),Qianwen Wang,Rokeya Tasneen,Sandeep Tyagi,Heena Soni,Andrew Garcia,(unknown),Martin Gengenbacher,Matthew Zimmerman,Min Xie,Jansy P. Sarathy,Tian J. Yang,Véronique Dartois,Eric L. Nuermberger,Radojka M. Savić	7
2	Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis 2024 ·Antimicrobial Agents and Chemotherapy ·Lourdes Encinas,Si-Yang Li,(unknown),Rokeya Tasneen,Sandeep Tyagi,Heena Soni,(unknown),(unknown),(unknown),(unknown),(unknown),Izidor Sosič,Stanislav Gobec,Alfonso Mendoza-Losana,Paul J. Converse,Khisi Mdluli,Nader Fotouhi,David Barros-Aguirre,Eric L. Nuermberger	3
3	Long-term effects of prenatal arsenic exposure from gestational day 9 to birth on lung, heart, and immune outcomes in the C57BL/6 mouse model 2023 ·Toxicology Letters ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Rokeya Tasneen,(unknown),Eric L. Nuermberger,Wayne Mitzner,Mark J. Kohr,Fenna C.M. Sillé	2
4	Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments 2022 ·Antimicrobial Agents and Chemotherapy ·(unknown),Allison Bauman,(unknown),Karen Rossmassler,(unknown),(unknown),Martin I. Voskuil,Maria Garcia‐Cremades,Rada Savic,Payam Nahid,Camille M. Moore,Rokeya Tasneen,Eric L. Nuermberger,Gregory T. Robertson,Nicholas D. Walter	12
5	An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis 2022 ·Frontiers in Immunology ·Styliani Karanika,James T. Gordy,(unknown),Theodoros Karantanos,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Samuel K. Ayeh,Rokeya Tasneen,Stefanie Krug,Carina Danchik,(unknown),(unknown),Richard B. Markham,Petros C. Karakousis	7
6	Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy 2021 ·American Journal of Respiratory and Critical Care Medicine ·Amit Kaushik,Nicole C. Ammerman,Rokeya Tasneen,Sophie Lachau‐Durand,Koen Andries,Eric L. Nuermberger	9
7	Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis 2021 ·Antimicrobial Agents and Chemotherapy ·Rokeya Tasneen,Deborah S. Mortensen,Paul J. Converse,Michael E. Urbanowski,Anna M. Upton,Nader Fotouhi,Eric L. Nuermberger,Natalie A. Hawryluk	13
8	Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model 2020 ·Antimicrobial Agents and Chemotherapy ·Deepak V. Almeida,Paul J. Converse,Till F. Omansen,Sandeep Tyagi,Rokeya Tasneen,Jeongjun Kim,Eric L. Nuermberger	19
9	Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis 2019 ·Antimicrobial Agents and Chemotherapy ·Jian Xu,Si-Yang Li,Deepak V. Almeida,Rokeya Tasneen,(unknown),Paul J. Converse,Anna M. Upton,Khisimuzi Mdluli,Nader Fotouhi,Eric L. Nuermberger	71
10	Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer 2018 ·PLoS neglected tropical diseases ·Paul J. Converse,Deepak V. Almeida,Rokeya Tasneen,Vikram Saini,Sandeep Tyagi,Nicole C. Ammerman,Si-Yang Li,Nicole M. Anders,Michelle A. Rudek,J Grosset,Eric L. Nuermberger	20
11	Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis 2017 ·Antimicrobial Agents and Chemotherapy ·Sang‐Won Park,Rokeya Tasneen,Paul J. Converse,Eric L. Nuermberger	3
12	In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1 2017 ·ACS Infectious Diseases ·Pooja Gopal,Rokeya Tasneen,Michelle Yee,Jean‐Philippe Lanoix,Jansy P. Sarathy,(unknown),Liping Li,Véronique Dartois,Eric L. Nuermberger,Thomas Dick	30
13	High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis 2016 ·Antimicrobial Agents and Chemotherapy ·Jean‐Philippe Lanoix,Rokeya Tasneen,Paul E. O’Brien,Jansy P. Sarathy,Hassan Safi,Michael L. Pinn,David Alland,Véronique Dartois,Eric L. Nuermberger	18
14	Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9 2016 ·Disease Models & Mechanisms ·Alvaro A. Ordoñez,Rokeya Tasneen,Supriya Pokkali,Ziyue Xu,Paul J. Converse,Mariah H. Klunk,Daniel J. Mollura,Eric L. Nuermberger,Sanjay K. Jain	47
15	Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions 2011 ·The Journal of Infectious Diseases ·Jamie Harper,Ciaran Skerry,S. Lindsey Davis,Rokeya Tasneen,(unknown),Igor Kramnik,William R. Bishai,Martin G. Pomper,Eric L. Nuermberger,Sanjay K. Jain	183
16	Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig 2010 ·Journal of Antimicrobial Chemotherapy ·Zahoor Ahmad,Eric Nuermberger,Rokeya Tasneen,Michael L. Pinn,Kathy N. Williams,Charles A. Peloquin,J Grosset,Petros C. Karakousis	42
17	Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis 2009 ·American Journal of Respiratory and Critical Care Medicine ·Kathy N. Williams,Steven J. Brickner,C. Kendall Stover,Tong Zhu,Adam Ogden,Rokeya Tasneen,Sandeep Tyagi,J Grosset,Eric L. Nuermberger	95
18	Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis 2008 ·Antimicrobial Agents and Chemotherapy ·Rokeya Tasneen,Sandeep Tyagi,Kathy N. Williams,J Grosset,Eric L. Nuermberger	77
19	Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model 2008 ·Antimicrobial Agents and Chemotherapy ·Kathy N. Williams,C. Kendall Stover,Tong Zhu,Rokeya Tasneen,Sandeep Tyagi,J Grosset,Eric L. Nuermberger	160
20	Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis 2008 ·Antimicrobial Agents and Chemotherapy ·Eric Nuermberger,Sandeep Tyagi,Rokeya Tasneen,Kathy N. Williams,Deepak V. Almeida,Ian M. Rosenthal,J Grosset	152

About Rokeya Tasneen

Rokeya Tasneen is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine, having authored 35 papers that have together received 1.7k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (30 papers), Mycobacterium research and diagnosis (15 papers) and Cancer therapeutics and mechanisms (11 papers). The work is most often cited by research in Infectious Diseases (1.4k citations), Molecular Medicine (189 citations) and Epidemiology (998 citations). Rokeya Tasneen has collaborated with scholars based in United States, China and France. Frequent co-authors include Eric L. Nuermberger, Kathy N. Williams, Sandeep Tyagi, J Grosset, Khisimuzi Mdluli, Deepak V. Almeida, Charles A. Peloquin, Si-Yang Li, Ian M. Rosenthal and Paul J. Converse. Their work appears in journals such as Nature Communications, American Journal of Respiratory and Critical Care Medicine and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact